Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)
Source: SeekingAlpha
2025-06-06 17:02:27 ET
Introduction
My last look at Voyager Therapeutics ( VYGR ) was September 2023. Voyager was developing a one-and-done Alzheimer’s gene therapy treatment. It was still seeking an IND, with a target in the first half of 2024. Moreover, partnerships with larger pharmaceutical companies, like Neurocrine Biosciences ( NBIX ), helped validate its technology. I recommended Buy, but with a “strong note of caution.”...
Read the full article on Seeking Alpha
For further details see:
Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)
Voyager Therapeutics Inc.
NASDAQ: VYGR
VYGR Trading
-9.95% G/L:
$4.435 Last:
474,633 Volume:
$4.85 Open:
VYGR Latest News
March 09, 2026 04:01:00 pm
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
VYGR Stock Data
$301,853,951
50,692,821
0.13%
37
N/A
Biotechnology & Life Sciences
Healthcare
US
Lexington
